RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passe...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire-AsiaNet/ -- - Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients
...
Authors: LATEST ASIANET NEWS RELEASES